GlassScriptPhysician profile
Gus A Gonzalez
NPI 1962497594
$7,107.68
in general payments reported to CMS, 2019-2025
69 companies · $2,917 in 2025
The $2,917 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,223 · 2020: $247 · 2021: $33.37 · 2023: $516 · 2024: $2,170 · 2025: $2,917.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,404 · Education: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,403.74 |
| Education | $199.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $693.11 | 2019-2025 | |
| Pfizer INC. | $454.08 | 2019-2025 | |
| Janssen Biotech, INC. | $429.48 | 2019-2025 | Erleada, Rybrevant, Darzalex |
| Merck Sharp & Dohme LLC | $374.46 | 2019-2025 | Keytruda, Lynparza, Welireg |
| Incyte Corporation | $368.28 | 2019-2025 | Jakafi, Monjuvi, Pemazyre |
| Astrazeneca Pharmaceuticals LP | $366.07 | 2019-2025 | Imfinzi, Calquence, Enhertu |
| Daiichi Sankyo INC. | $300.34 | 2023-2025 | Enhertu, Injectafer |
| Lilly USA, LLC | $297.90 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Regeneron Healthcare Solutions, INC. | $213.28 | 2019-2025 | Libtayo |
| Amgen INC. | $188.93 | 2019-2024 | Blincyto, Kyprolis |
| Abbvie INC. | $172.95 | 2019-2025 | |
| Glaxosmithkline, LLC. | $163.11 | 2024-2025 | Ojjaara, Jemperli, Zejula |
| Emd Serono, INC. | $144.27 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $128.85 | 2024-2025 | Ninlaro, Alunbrig |
| Bayer Healthcare Pharmaceuticals INC. | $126.31 | 2019-2024 |
Show all 69 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gus Gonzalez listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.